Covid19, Geriatric Medicine, Immunosenescence, Seroconversion
Conditions
Keywords
Covid19, geriatric medicine, seroconversion, immunosenescence
Brief summary
This study aims to determine how long COVID-19 neutralizing antibodies can be detected in an elderly institutionalized population presenting fragility factors. This study also aims to stratify seroconversion by immunological profiles of the elderly patients residing in the EHPAD. This stratification requires the measurement of immunological marker levels already described in immunosenescence and also involved in the development of certain chronic infectious diseases more common in the elderly population. This analysis will enable the investigators to describe an immunological, clinical and biological profile representing a patient who has developed an immunity against COVID 19. It will also help the investigators to understand the different mechanisms leading to a reduced immune response after a potential administration of a vaccine. Finally, it will help describe the immune profiles of elderly residents who presented with non-severe forms of COVID-19.
Interventions
BIOLOGICALblood sample
Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.
Sponsors
Centre Hospitalier Universitaire, Amiens
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Residents of the EHPAD/USLD St Victor of the Amiens CHU who took part in the screening campaign (RT-PCR and serology) organized by the Amiens CHU * residents who signed a consent form to participate in the study
Exclusion criteria
* The patient or his legal representative refused to participate in the study * Heavily sedated patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| titers of COVID-19 neutralising antibodies | day 0 |
Countries
France
Outcome results
None listed